

### REMARKS

Applicants have amended the paragraph beginning on page 2, line 16, of the specification as filed to recite SEQ ID NOs.: 1 and 7, and have further amended the paragraph beginning on page 35, line 10, of the specification as filed to recite SEQ ID NO.: 7. Applicants have also amended the specification to replace the originally filed Sequence Listing with the Sequence Listing provided herewith, which features SEQ ID NO.: 7. In addition, applicants have amended claim 2 to recite a polypeptide having an amino acid sequence consisting of SEQ ID NO.: 7, and have amended claim 7 to depend from claim 2 as amended. Support for these amendments can be found, e.g., on page 35, lines 11-16, of the application as filed. No new matter has been added by any of the foregoing amendments.


As required by the Notice to Comply, Applicants provide herewith a substitute paper copy and a computer readable form (CRF) copy of the Sequence Listing.

If there are any charges or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: MAY 7, 2008

  
for James D. DeCamp, Ph.D.  
Reg. No. 43,580

MICHAEL A. ROBINSON, Ph.D.  
REG. NO. 57,903

Clark & Elbing LLP  
101 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045